The masthead · Who publishes this
About PT-141 Medicinal
An independent editorial ledger of the published research on PT-141 — what the studies measured, balanced against what stays unsettled.
What this site is
PT-141 Medicinal is an independent editorial project that publishes plain-English summaries of the peer-reviewed research literature on PT-141 (bremelanotide). We are not a clinic. We do not employ clinicians and we do not provide medical advice. We do not manufacture, sell, or distribute any product. Our work is editorial commentary on publicly available science.
The site is organized as a ledger because the evidence asks for it. PT-141 is an FDA-approved drug with real, quantified human data — two Phase 3 trials, a year-long extension, a mechanistic imaging study, a detailed label — alongside honest qualifications, from the small-effect-size critique to the premenopausal-women-only boundary. A balanced account puts the measured findings in one column and the caveats in another, and cites both.
What 'medicinal' means here, and what it doesn't
The word "medicinal" in this site's name is editorial framing — a position the publisher takes toward the literature, treating PT-141 as a regulated medicine with a documented record worth reading carefully. It is not a claim that this site offers treatment, consultation, prescriptions, or any product.
We do not run a pharmacy or a storefront. We do not sell PT-141 or anything else, and we point to no vendor. Where the research describes a dose, we report it as a documented study or label figure, in the third person, never as advice for any individual. Decisions about any medicine belong with a qualified prescriber, not a website.
How we work
Each page is built from the published record: the peer-reviewed trial literature, the FDA prescribing information, and the most recent studies, with every quantitative claim tied to a numbered source on the references page. We surface the recent and authoritative evidence first, and we keep the off-label and research-grade claims clearly labeled as such.
Where the evidence is contested — as it is for the size and meaning of bremelanotide's effect — we present both the supportive and the critical readings rather than choosing one. The goal is an account a careful reader can trust and verify, not a sales pitch and not a scare piece.